CARBAMIC ACID,(1,2,3-THIADIAZOLE-4-YLCARBONYL)-,OMEGA-BROMO-DECYL ESTER


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ONCOGXJJGARMDO-UHFFFAOYSA-N
Smiles	BrCCCCCCCCCCOC(=O)NC(=O)c1csnn1
InChI	InChI=1S/C14H22BrN3O3S/c15-9-7-5-3-1-2-4-6-8-10-21-14(20)16-13(19)12-11-22-18-17-12/h11H,1-10H2,(H,16,19,20)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C14H22BrN3O3S
Molecular Weight	392.31
AlogP	4.63
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	12.0
Polar Surface Area	109.42
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	22.0

Assay Description	Organism	Bioactivity
Fungistatic activity against Alternaria kikuchiana assessed as inhibition of mycelial growth measured at 5 ug/mL at 28 degC after 72 hr relative to control	Alternaria kikuchiana	0.0 %
Fungistatic activity against Alternaria kikuchiana assessed as inhibition of mycelial growth measured at 50 ug/mL at 28 degC after 72 hr relative to control	Alternaria kikuchiana	41.0 %
Fungistatic activity against Fusarium graminearum assessed as inhibition of mycelial growth measured at 5 ug/mL at 28 degC after 72 hr relative to control	Fusarium graminearum	25.0 %
Fungistatic activity against Fusarium graminearum assessed as inhibition of mycelial growth measured at 50 ug/mL at 28 degC after 72 hr relative to control	Fusarium graminearum	42.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2252739
PubChem	11383768

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).